Bone Biologics Corp. (NASDAQ:BBLG) Sees Significant Drop in Short Interest

Bone Biologics Corp. (NASDAQ:BBLG) saw a large drop in short interest in the month of July. As of July 15th, there was short interest totaling 26,560 shares, a drop of 60.5% from the June 30th total of 67,279 shares. Based on an average trading volume of 70,934 shares, the short-interest ratio is currently 0.4 days. Approximately 1.6% of the shares of the stock are sold short.

Bone Biologics Stock Performance

Shares of NASDAQ BBLG opened at $1.07 on Monday. The stock has a market cap of $1.94 million, a price-to-earnings ratio of -0.47 and a beta of 0.90. Bone Biologics has a 52 week low of $1.05 and a 52 week high of $4.13. The company’s 50-day moving average price is $1.29 and its 200 day moving average price is $1.33.

Bone Biologics (NASDAQ:BBLG) last posted its earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter, meeting the consensus estimate of ($0.43). As a group, research analysts expect that Bone Biologics will post -1.17 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Bone Biologics presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC increased its stake in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the period. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. 34.30% of the stock is currently owned by institutional investors.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.